EYSINS, Switzerland, Feb. 10, 2025 /PRNewswire/ -- AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® Celiac ...

EYSINS, Switzerland, April 3, 2025 /PRNewswire/ --Today, AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® ...

PathogenDx's breakthrough technology shifts the pathogen detection paradigm from microbial to molecular testing through its microarray assays, namely DetectX, EnviroX, and QuantX SANTA CLARA, ...

Systemic autoimmune Rheumatic Diseases such as Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus, Systemic Sclerosis (also known as Scleroderma), Sjögren's syndrome, idiopathic inflammatory ...

All reagents and multiplex microarray magazines are equipped with RFID tags to save time while avoiding manual errors. Unique combination of tests The MosaiQ AiPlex CTDplus assay enables a syndromic ...

The MosaiQ AiPlex CD is designed to improve the accuracy and speed of celiac disease diagnosis while simplifying laboratory workflows The MosaiQ AiPlex CD multiplex assay, which received IVDR-CE mark ...

AliveDx, a company that develops in-vitro diagnostic solutions to help patients get diagnosed and treated faster, announces the receipt of IVDR-CE mark for its MosaiQ AiPlex CTDplus multiplex assay.

The MosaiQ AiPlex CD is designed to improve the accuracy and speed of celiac disease diagnosis while simplifying laboratory workflows EYSINS, Switzerland, Feb. 10, 2025 /PRNewswire/ -- AliveDx ...

As sequencing projects of microbial organisms are being completed, a large number of genes of potential biological and medical relevance are classified as 'unknown' because their unique sequence and ...

MiRNA microarray kits and reagents market is experiencing robust growth driven by rising demand for precision diagnostics, biomarker discovery, and translational research. Expansion of oncology ...

MiRNA microarray kits and reagents market is experiencing robust growth driven by rising demand for precision diagnostics, biomarker discovery, and translational research. Expansion of oncology ...